What is Champions Oncology's market cap?

Champions Oncology (CSBR) has a market capitalization of $68.4M and trades on NASDAQ.

Who are Champions Oncology's competitors?

Champions Oncology's key competitors include Charles River Laboratories, Labcorp, Compass Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Champions Oncology partner with?

Champions Oncology's notable partners include Marriott International, Inc..

What subsidiaries does Champions Oncology have?

Champions Oncology's subsidiaries include Biomerk, Inc..

Where is Champions Oncology headquartered?

Champions Oncology is headquartered in United States of America and employs approximately 306 people. It has been publicly traded since 1994.

Champions Oncology (CSBR) Stock Fundamentals & Financials

Champions Oncology is a technology-enabled research organization that provides advanced computational and experimental platforms for drug discovery and development.

Market cap

$68.36M-24.9%

Earnings

Q2 2026 report

July 27, 2026

Revenue$13.8MBeat by $949.0K EPS$0.01Beat by $0.06

Read the full report

Next report

Sep 14, 2026 (In 2 weeks)

Revenue estimate$15.0M

EPS estimate-$0.01

Competitors

By market cap

Labcorp Holdings$27.2B+17.3%

Charles River Laboratories$14.1B+75.8%

NeoGenomics$2.2B+144%

Fortrea Holdings Inc.$1.8B+115%

Compass Therapeutics, Inc.$437.6M-3.5%

Champions Oncology$68.4M-24.9%

Harvard Bioscience$34.8M+46.4%

VivoSim Labs$3.9M-18.5%

By revenue growth

NeoGenomics+11.2%

Labcorp Holdings+6.4%

Charles River Laboratories-0.7%

Fortrea Holdings Inc.-2.1%

By net margin

Labcorp Holdings6.99%+1.3pp

Fortrea Holdings Inc.-3.18%+34.4pp

Charles River Laboratories-5.96%-12.0pp

NeoGenomics-6.77%+8.3pp

Profile

Champions Oncology is a technology-enabled research organization that provides advanced computational and experimental platforms for drug discovery and development. The company leverages a proprietary bank of Patient Derived Xenograft (PDX) models and a massive oncology dataset to help biopharmaceutical companies predict drug efficacy and identify novel therapeutic targets. Its core value proposition lies in its ability to simulate human clinical trial results through highly characterized biological models and AI-driven analytics.

Competitive position

A leading provider of PDX-based oncology research services with a proprietary bank of approximately 1,500 models and a unique living Datacenter.

GeographiesNorth America, Europe, Asia

Customer segmentsBiopharmaceutical companies, Academic institutions, Governmental agencies

Business modelB2B Service, Subscription SaaS, IP Licensing

SuppliersClinical networks for tumor samples, Hospitals and academic medical centers, Laboratory equipment suppliers, Specialized animal model suppliers

CustomersGlobal biopharmaceutical companies, Clinical-stage biotech firms, Oncology research scientists

CountryUnited States of America

Listed1994

Employees306.0

CEORobert Brainin

SectorHealthcare

IndustryBiotechnology

Websitechampionsoncology.com

FilingsSEC EDGAR

FAQ

What is Champions Oncology's market cap?: Champions Oncology (CSBR) has a market capitalization of $68.4M and trades on NASDAQ.
Who are Champions Oncology's competitors?: Champions Oncology's key competitors include Charles River Laboratories, Labcorp, Compass Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Champions Oncology partner with?: Champions Oncology's notable partners include Marriott International, Inc..
What subsidiaries does Champions Oncology have?: Champions Oncology's subsidiaries include Biomerk, Inc..
Where is Champions Oncology headquartered?: Champions Oncology is headquartered in United States of America and employs approximately 306 people. It has been publicly traded since 1994.